In univariate analysis, tumor size ≥ 2 cm (P = 0.001), low differentiation (P = 0.005), NSCLC patients with stage IV (P < 0.001), brain metastases (P < 0.001), bone metastases (P = 0.017), hepatic metastases (P < 0.001), PD-L1 expression < 1% (P < 0.001), and lower baseline AC of CD3+ (P < 0.001), CD4+(P < 0.001), CD8+ (P < 0.001), B (P < 0.001) and NK cells (P < 0.001) were associated with shorter PFS. This evidence concerns the gene CD4 and neoplasm.